Dexamethasone in the Prevention of Post-spinal Paralytic Ileus After Cesarean Section

Launched by ASSIUT UNIVERSITY · Dec 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called Dexamethasone can help prevent a condition known as postoperative ileus, which is a slowdown or stoppage of the intestines after surgery. This trial is specifically looking at women who are having a cesarean section, a common surgical procedure for delivering babies. Postoperative ileus can make recovery more difficult, so finding ways to prevent it is important for better patient outcomes.

To be eligible for this study, participants must be women aged 18 to 40 who are having a scheduled cesarean section and are generally healthy, classified as ASA class I or II. They must also be pregnant with one baby and at least 32 weeks along. Before joining, all participants will need to agree to the study by signing a consent form. If you join this trial, you can expect to receive the study medication and be monitored closely for any changes in your recovery after the surgery. The trial is currently recruiting participants, so it's a good opportunity for those who meet the criteria to contribute to important medical research.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • •All participants will sign an informed consent prior to inclusion in the study.
• • All patients 18-40 years of full-term singleton pregnancy (37-41 weeks).,
• • American Society of Anaesthesiologists (ASA) classification class I and II scheduled.
• • for elective or semi-elective surgery (category 3 and 4 Caesarean sections).
• • All patients under spinal anesthesia for a Single baby pregnancy of more than 32 weeks will be included in this study.
• Exclusion Criteria:
• • will be patients' height \< 150 or \> 180 cm.
• • Body mass index (BMI) \>35 kg m-2.
• • Contraindication or refusal to undergo regional anesthesia.
• • any cardiovascular disease including arrhythmias and severe stenotic valvular heart disease.any renal or hepatic diseased patients.